Pear Therapuetics (Pear) recently raised $64 million, in addition to launching a new prescription app for opioid use-related addiction disorder. The news comes shortly after the organization recently received clearance from the U.S. Food and Drug Administration (FDA) for reSET-O, its prescription software for the treatment of opioid use-related addiction disorder.
It is anticipated that the funding will go towards expansion of Pear’s global reach, in addition to helping the organization acquire new assets and bolster its development of products aimed at conditions such as schizophrenia. The organization continues its uphill battle to convince provider organizations and health care consumers alike that its softwares can be used as stand-alone treatments, seeking to prove the efficacy of its treatments and their ability to be reimbursed.
Pear Therapeutics operates primarily in the electro-medical equipment industry. The organization is focused on the development of prescription digital therapeutics to treat diseases with high unmet medical needs.
This was reported by Fierce Biotech on January 9, 2019.
Contact Information: Pear Therapeutics, 745 Atlantic Avenue, Boston, Massachusetts 02111; (617) 545-3486; Website: www.peartherapeutics.com